# e-BLOT

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/e-blot

- Industry: Medical Devices & Equipment
- Headquarters: Shanghai, China
- Website: www.e-blot.com
- Latest round: Series A (Jul 13, 2026)
- Investors on record: 1

## About

Based in Shanghai, China and established in 2017, e-BLOT Life Science (Shanghai) Co., Ltd., trading as e-BLOT, is a medical company that provides imaging instrument for protein life science. The company was recognized as a high-tech enterprise in Shanghai. Tao Zhang, CEO of the company, has a master's degree in Microbial Genetic Engineering from Chongqing University and has over 10 years of experience in the life science instrumentation industry. He was formerly the Application Marketing Manager & Regional Sales Manager of the Life Science Department in Jena, Germany. In July 2026, e-BLOT raised a series A funding from Real Power Capital.

The company's main business is providing contact chemiluminescence imagers.

The company's revenue is generated by selling EZ BLOT one-touch wet transfer system and touch imager.

The company will use the latest funding to advance the next-generation development of its contact imaging and contact wet transfer technology platforms, accelerate its international expansion, strengthen its R&D, manufacturing, and service capabilities, and further expand its end-to-end protein immunoblotting product portfolio.

## Funding rounds

- Series A, Jul 13, 2026 — Real Power Capital

## Investors

- Real Power Capital (https://capitalatlas.ai/funds/real-power-capital) — Series A